When it comes to innovation and longevity, the latest name that resonates in the corridors of Silicon Valley is that of Retro Biosciences. Behind doors that until recently were closed to the world, lies a one-of-a-kind laboratory. Here, under the guidance of Joe Betts-LaCroix (and the backing of a huge investment from OpenAI's CEO Sam altman), a team of bold and visionary researchers works with a practical and concrete goal. Which? That of extending human life by ten years, taking advantage of the most recent discoveries in the field of biotechnology.
An innovative approach to research
The philosophy of Retro Biosciences deviates significantly from the conventions of the biotechnology industry. Instead of focusing on a single promising discovery, the startup has decided to follow five different research paths simultaneously.
It is a high risk and very expensive strategy. It can only survive at the moment thanks to the massive help of its main investor. Sam Altman provided the startup with $180 million, and now Retro has the freedom to explore several parallel avenues in its quest for longevity.
What are the five research lines of Retro Biosciences?
- Autophagy (Removal of Damaged Cells). This area of research aims to understand and enhance the body's natural process of eliminating damaged or dysfunctional cells.
- Blood Plasma Rejuvenation. This strand focuses on rejuvenating blood plasma, based on studies showing benefits for older organisms when infused with plasma from younger organisms.
- Three Research Programs Related to Partial Cellular Reprogramming. Partial cellular reprogramming is a process in which cells from an older organism can be treated to return to a more youthful state. Retro Biosciences is working on three different programs in this area, building on scientific discoveries that have demonstrated the feasibility of this process in animal experiments. to. Reprogramming of T-Cells for Cancer. A specific project in this area aims to reprogram T-cells to improve their effectiveness in attacking solid tumors. b. There Reprogramming of Liver Cells. This project focuses on rejuvenating liver cells to return them to a more youthful state. c. Reprogramming of the Immune System. Led by the scientist Anastasia Shindyapina, this program aims to renew the human immune system, with the aim of improving the body's ability to fight disease and repair itself more effectively, as occurs in youth.
These lines of research reflect a broad and diversified approach by Retro Biosciences, but this is not the only "breaking" choice made by the startup.
The creation of an unconventional laboratory
Betts-LaCroix's urgent desire to start experiments led to the birth of an unusual approach. Instead of the normal expense of $15 million and extended construction time for a similarly sized lab, Retro Biosciences built its lab for just $200.000.
As? Using an abandoned commercial building in Redwood City California and shipping containers that would soon be used to house mouse experiments in very short order.
The ambitions of Retro Biosciences
Retro Biosciences' research focuses primarily on partial reprogramming of cells, a process demonstrated in numerous animal experiments, in which cells from an aged organism can be treated with a combination of proteins or molecules and rejuvenated.
A very serious approach, based on Nobel-winning knowledge, and considered by Retro and other startups as the most promising longevity technology to have emerged so far.
Silicon Valley has been hoping to delay aging for years, and basically to find a real “cure” for death. After the epics of Alphabet (with Calico) and Amazon (with Altos Labs which has 3 billion in funds behind it), Retro Biosciences and its counterparts think this time is different. Many startup researchers believe that the science behind cellular reprogramming is now mature, and that therapies are now a purely organizational problem. They see slowing down old age as not just achievable, but imminent. It's true?
A promising, but uncertain future
Despite the enormous potential, the road to safe and approved treatments is still long and full of unknowns. Even the most promising research in biotechnology has often faced obstacles in proving the merits and safety of their products.
Retro Biosciences, with its bold strategy and significant financial support, positions itself at the forefront of this challenge. Another vanguard that will seek to decipher and exploit the secrets of the human body for a longer and healthier future. Good luck and good work.
Comments are closed.